Skip to main content
. 2021 Oct;10(10):4478–4488. doi: 10.21037/tcr-21-1940

Figure 2.

Figure 2

Downregulation of MCM3AP-AS1 inhibits cell growth and induces apoptosis of breast cancer cells. (A) Relative expression of MCM3AP-AS1 in the indicated stable cell lines. (B) Downregulation of MCM3AP-AS1 substantially inhibits the proliferation of MDA-MB-231 (left panel) and ZR-75-30 (right panel) using the MTT assay. (C) Representative images (left panel) and quantitative analysis (right panel) of the indicated cell lines using colony formation assays. (D) Representative images (left panel) and quantitative analysis (right panel) of the indicated cell lines using anchorage-independent growth assays. (E) Downregulation of MCM3AP-AS1 increases the number of TUNEL ± cells compared with the scramble group under the treatment with sorafenib. (F) Representative image of apoptotic cells from a flow cytometry assay. (G) Apoptotic cells in different cell lines. (H) Flow cytometry assay showing that downregulation of MCM3AP-AS1 results in cell cycle G1 phase arrest in MDA-MB-231 (left panel) and ZR-75-30 (right panel) cells. (I) The representative image of cell cycle. *, P<0.05; **, P<0.01; ***, P<0.001. MCM3AP-AS1, maintenance complex component 3 associated protein antisense RNA 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TUNEL, terminal deoxynulceotidyl transferase nick-end-labeling.